NCT05057130View on ClinicalTrials.gov

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

OsteosarcomaNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueSarcomaSarcoma of Bone

Interventions

DRUG

Doxorubicin, Cisplatin, Methotrexate

DRUG

Doxorubicin, Cisplatin

Trial Locations (1)

115478

RECRUITING

"Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation", Moscow

All Listed Sponsors

lead

Blokhin's Russian Cancer Research Center

OTHER